JIC Plans JSR Sale to Mitsui Chemicals for More Than $8.2 Billion as Funding Concerns Hit Shares

A proposed deal bigger than the buyer's market value

Japan Investment Corp plans to sell semiconductor materials maker JSR to Mitsui Chemicals in a transaction that could exceed 1.3 trillion yen ($8.2 billion), according to two people familiar with the matter. Mitsui Chemicals shares fell 13% after the plan became public on November 4, as investors focused on the financial burden of buying a business for more than the buyer's own stock market value.

The state backed investment fund bought JSR for about 900 billion yen in 2024, intending to make it a platform for combining businesses in Japan's semiconductor materials industry. A sale would instead transfer that task to a domestic chemical manufacturer while rising investment in artificial intelligence supports higher valuations for businesses connected to chip production.

One person familiar with the discussions said a decision could come within November. JIC, JSR and Mitsui Chemicals had not responded to requests for comment when the plan was reported. The final price, financing structure and completion timetable have not been announced.

The proposed purchase brings together two different calculations. JSR could strengthen Mitsui Chemicals in materials that chip factories need to make electronic circuits. Paying for it would stretch a company whose market capitalisation was about 800 billion yen, compared with a potential transaction value above 1.3 trillion yen.

Why JSR matters to chip manufacturing

JSR, established in 1957 and based in Tokyo's Minato district, is a leading manufacturer of photoresists. These are chemicals used to transfer circuit patterns onto semiconductor wafers, the thin discs on which chips are made.

A photoresist works somewhat like a light sensitive stencil. Manufacturers coat a wafer with it, expose selected areas to light and develop the resulting pattern. That pattern guides later processing steps that create the tiny structures inside a chip.

JSR's appeal therefore reaches beyond ordinary chemical production. Its materials play a direct role in the precision work needed to manufacture semiconductors. Mitsui Chemicals has also been expanding its chip materials business, giving the proposed acquisition a clear connection to its existing direction.

JSR strengthened its technology portfolio in October 2021 by making Inpria a wholly owned subsidiary. Inpria develops metal based resists for extreme ultraviolet lithography, known as EUV. This manufacturing technique uses light with a very short wavelength to create extremely small circuit patterns.

Spending on artificial intelligence has increased demand for computing capacity and investment in the semiconductor industry. Higher valuations for businesses connected to that investment give JIC an opportunity to seek a substantially higher price than it paid roughly two years earlier.

The price increase since JIC's purchase

A transaction at 1.3 trillion yen would be about 400 billion yen above JIC's approximately 900 billion yen acquisition price, an increase of roughly 44%. Because the proposed value could exceed 1.3 trillion yen, the eventual difference could be larger.

JIC's eventual investment return would depend on transaction expenses, financing costs, changes in the businesses being sold and the final agreement. JSR has undergone changes since the takeover, including a planned disposal in its life sciences operations.

The proposed sale could rank among the largest transactions in Japan's chemicals industry. It could exceed Showa Denko's 2020 acquisition of Hitachi Chemical, the combination that created Resonac Holdings.

Mitsui Chemicals would be making a purchase equal to more than 1.6 times its approximately 800 billion yen market value. Market capitalisation is the value investors assign to a company's shares. It helps show the scale of this purchase relative to the buyer, while cash and borrowing capacity determine how the company can fund it.

Why investors focused on financing

Mitsui Chemicals had 217.8 billion yen in cash and cash equivalents at the end of June, alongside 876.4 billion yen in debt carrying interest. Its debt to equity ratio was 0.75, meaning it had 75 yen of such debt for every 100 yen of equity.

A purchase costing 1.3 trillion yen would be almost six times that cash balance. The reported cash would cover about 17% of the price, leaving a difference of roughly 1.08 trillion yen before accounting for other funding sources or the cash needed to keep the existing business running.

Tsutomu Yamada, an analyst at Mitsubishi UFJ eSmart Securities, linked the share decline to the amount Mitsui Chemicals might need to raise.

"Concern about the substantial amount of funding needed appear to have come to the fore," said Yamada.

Possible funding routes include borrowing, issuing shares or selling assets. Each would affect investors differently. Borrowing adds interest payments and repayment obligations. Issuing shares spreads ownership across more shares, reducing the percentage held by existing investors unless they buy more. Selling assets raises cash but also removes businesses and their future earnings.

Mitsui Chemicals would also need to manage the purchase alongside its existing debt. Investors will therefore be looking at both the source of the money and how the combined business would generate enough cash to support the enlarged company.

JIC changes the route to industry consolidation

JIC was established in 2018 and is overseen by Japan's trade ministry. Its purpose is to invest in companies in ways that strengthen Japan's competitiveness. Its investments also include medical equipment manufacturer Topcon alongside private equity firm KKR.

JSR approached JIC Capital about going private in November 2022. At the time, JSR saw a need to combine businesses in semiconductor materials, but resistance among other companies made that difficult.

Taking JSR off the stock exchange placed it under a controlling owner able to pursue a longer investment plan. JSR had envisaged returning to the stock market five to seven years after going private, following work to increase its corporate value.

A sale to Mitsui Chemicals would replace that intended route with ownership by an operating company. The fund would exit, while Mitsui Chemicals would take responsibility for fitting JSR into its own materials business and turning the combination into stronger earnings.

Japan's industrial objective would still run through the transaction: building competitive suppliers for semiconductor manufacturers. The immediate change would be who provides the capital, carries the financial risk and makes decisions about the business.

How JSR moved from the stock market to a possible sale

JSR's transition took several years, with the original takeover delayed by competition procedures in China. A tender offer, the method used for the acquisition, invites shareholders to sell their shares at a stated price during a specified period.

• October 2021: JSR made Inpria a wholly owned subsidiary, securing technology for metal based resists used in EUV manufacturing.
• November 2022: JSR approached JIC Capital about taking the company private.
• June 26, 2023: JSR supported a tender offer by JIC subsidiary JICC-02 at 4,350 yen per share.
• March 19, 2024: The tender offer began after a delay involving competition procedures in China.
• April 16, 2024: The offer succeeded, attracting about 175.27 million shares and representing 84.36% of voting rights.
• April 23, 2024: JICC-02 became JSR's parent company.
• June 25, 2024: JSR was delisted from the Tokyo Stock Exchange.
• April 2025: JSR announced the sale of its diagnostic pharmaceuticals business to Tokuyama at an equity value of 82 billion yen.
• November 4, 2026: The planned sale to Mitsui Chemicals became public, with a decision potentially coming within the month.

The original tender offer valued the planned share purchases at approximately 903.8 billion yen. That more precise figure is consistent with the roughly 900 billion yen price used to describe JIC's acquisition.

JSR's restructuring extends beyond semiconductors

JSR's finances also reflect difficulties in life sciences. For the financial year ended March 2025, a goodwill impairment of 139.3 billion yen in that business contributed to an operating loss of 209.1 billion yen.

Goodwill is an accounting value created when a company pays more for an acquired business than the value assigned to its identifiable net assets. An impairment reduces that recorded value when expectations for the acquired business fall.

The size of the charge shows why JSR's investment story includes more than demand for chip materials. A prospective owner would be taking on a company that has also been dealing with the financial consequences of earlier expansion in another industry.

JSR's April 2025 announcement concerning the diagnostic pharmaceuticals business put an equity value of 82 billion yen on the planned sale to Tokuyama. Equity value is the amount assigned to ownership of the business, with debt and other transaction adjustments handled according to the agreement.

The strategic prize and the financial test

Mitsui Chemicals could gain a stronger position in a specialised part of semiconductor manufacturing through JSR's photoresists and related technology. The combination would bring those capabilities into a company already expanding in chip materials.

Yamada, the Mitsubishi UFJ eSmart Securities analyst, also described the potential benefit for Mitsui Chemicals and how investors might eventually value it.

"Adding JSR's semiconductor strengths could boost its presence in the sector and lead to a re-rating," said Yamada.

A re-rating means investors become willing to pay a different valuation for a company, for example because they expect a more attractive mix of businesses or stronger earnings. For Mitsui Chemicals, achieving that outcome would require the industrial benefits of JSR to outweigh the cost of purchasing and financing it.

JIC faces a different calculation: whether selling into stronger valuations offers a better exit than continuing toward the previously envisaged stock market return. For Mitsui Chemicals shareholders, the central issue is whether the price and funding terms leave enough room for the acquisition to create value.

Key Points

• JIC plans to sell JSR to Mitsui Chemicals for potentially more than 1.3 trillion yen, or $8.2 billion.
• A decision could come within November 2026; final terms and a completion date have not been announced.
• Mitsui Chemicals shares fell 13% as investors focused on financing.
• The potential price exceeds Mitsui Chemicals' approximately 800 billion yen market value and is almost six times its reported June cash balance.
• JSR supplies photoresists used to create circuit patterns during semiconductor manufacturing.
• A sale would shift JSR from state backed fund ownership to a domestic chemical manufacturer, replacing an earlier plan for an eventual stock market return.